Role of regulatory miRNAs of the PI3K/AKT/mTOR signaling in the pathogenesis of hepatocellular carcinoma | Zendy

Rahmani Farzad | Zendy; Ziaeemehr Aghigh | Zendy; Shahidsales Soodabeh | Zendy; Gharib Masoumeh | Zendy; Khazaei Majid | Zendy; Ferns Gordon A. | Zendy; Ryzhikov Mikhail | Zendy; Avan Amir | Zendy; Hassanian Seyed M. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Role of regulatory miRNAs of the PI3K/AKT/mTOR signaling in the pathogenesis of hepatocellular carcinoma

Author(s) -

Rahmani Farzad,

Ziaeemehr Aghigh,

Shahidsales Soodabeh,

Gharib Masoumeh,

Khazaei Majid,

Ferns Gordon A.,

Ryzhikov Mikhail,

Avan Amir,

Hassanian Seyed M.

Publication year - 2020

Publication title -

journal of cellular physiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.529

H-Index - 174

eISSN - 1097-4652

pISSN - 0021-9541

DOI - 10.1002/jcp.29333

Subject(s) - pi3k/akt/mtor pathway , protein kinase b , microrna , cancer research , hepatocellular carcinoma , biology , signal transduction , phosphoinositide 3 kinase , rptor , pathogenesis , kinase , microbiology and biotechnology , immunology , gene , genetics

Abstract Hepatocellular carcinoma (HCC) is one of the common malignant human tumors with high morbidity worldwide. Aberrant activation of the oncogenic phosphoinositide 3‐kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling is related to clinicopathological features of HCC. Emerging data revealed that microRNAs (miRNAs) have prominent implications for regulating cellular proliferation, differentiation, apoptosis, and metabolism through targeting the PI3K/AKT/mTOR signaling axis. The recognition of the crucial role of miRNAs in hepatocarcinogenesis represents a promising area to identify novel anticancer therapeutics for HCC. The present study summarizes the major findings about the regulatory role of miRNAs in the PI3K/AKT/mTOR pathway in the pathogenesis of HCC.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research